Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer

Table 4 Summary of the data after bevacizumab-combined chemotherapy as second- and later-line treatment in patients with metastatic colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

Ref.	Treatment line	Treatment regimen	n	ORR (%)	Median PFS (mo)	Median OS (mo)
Giantonio et al[12]	Second	BV + FOLFOX4	287	22.7	7.3	12.9
		FOLFOX4	285	8.6	4.7	10.8
		BV	234	3.3	2.7	10.2
Yildiz et al[20]	Second	BV + Irinotecan-based therapy	40	20.0	6.0	14.0
Chen et al[14]	Third	BV + FU/LV	100	4.0	3.7	9.1
Kwon et al[21]	Third	BV + FOLFIRI	14	28.5	3.9	10.9
Lièvre et al[22]	Second or later-line	BV + FOLFIRI or FOLFOX	31	32.2	9.7	18.4
Kang et al[16]	Third or later-line	BV + FOLFIRI or FOLFOX	42	9.5	5.3	9.5
Park et al	Second or later-line	BV + FOLFIRI or FOLFOX	40	7.5	6.13	14.0

BV: Bevacizumab; FOLFOX4: Fluoropyrimidine + oxaliplatin; FOLFIRI: Fluoropyrimidine + irinotecan; FU/LV: Fluoropyrimidine + leucovorin; OS: Overall survival; PFS: Progression-free survival; ORR: Overall response rate.